Common Asthma Medicine Reduces Need For COVID-19 Hospitalization: Oxford Study

Feb 9 (Reuters) – A commonly used asthma treatment could reduce the need to hospitalize COVID-19 patients if the drug is given within seven days of symptoms, British researchers said on Tuesday.

Budesonide, sold under the brand name Pulmicort by AstraZeneca Plc and also used to treat smoker’s lung, reduced the time it took for patients to recover from COVID-19 also when administered by inhaler, said the University of Oxford. (https://bit.ly/3q40g1W) (Report by Pushkala Aripaka in Bengaluru Edited in Spanish by Javier López de Lérida)

READ MORE WAB NEWS

RELATED

YOU MAY ALSO LIKE